RxDoctor Payments Data

Cameron Peterson, MD

Physical Medicine & Rehabilitation · Logan, UTNPI 1164604765

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,006 of the $1,311 with a category attached, or 76.7%. 4 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 51.3% of the total. Reporting peaked in 2023 at $932 and has fallen 87.6% since, to $116 in 2025.

$1,311in general payments, 2019–2025

Across 22 payments — averaging $59.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$673
  • Curonix LLC$474
  • Teva Pharmaceuticals USA, Inc.$131
  • Shire North American Group Inc$33

What the payments were for

  • Travel & lodging$28822%
  • Food & beverage$1,00677%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,311 in reported general payments places this provider in the 70th percentile of 117 physical medicine & rehabilitation providers in Utah.

See all physical medicine & rehabilitation providers in Utah

Medicare billing

Part B allowed, 2024
$371,085
Medicare patients
481
Services billed
3,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$118,390
JardianceEmpagliflozin51$17,282
XareltoRivaroxaban52$14,302
TrulicityDulaglutide13$11,437
EntrestoSacubitril/Valsartan29$10,947
LinzessLinaclotide12$7,656
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$5,688
LokelmaSodium Zirconium Cyclosilicate15$5,461
Breo ElliptaFluticasone/Vilanterol12$5,140
JanuviaSitagliptin Phosphate16$4,740
FarxigaDapagliflozin Propanediol15$4,638
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,389
Incruse ElliptaUmeclidinium Bromide20$3,715
Atorvastatin Calcium227$3,479
MyrbetriqMirabegron13$3,417

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in Logan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →